Default company panoramic image
Logo

NeuMedics Inc.

NeuMedics is developing proprietary eyedrops to treat inflammatory eye diseases including Diabetic Macular Edema, Trauma and Dry Eye all unmet medical needs

  • Stage Product In Development
  • Industry Biotechnology
  • Location Seattle, WA, US
  • Currency USD
  • Founded August 2008
  • Employees 3
  • Incorporation Type C-corp
  • Website NeuMedics.com

Company Summary

NeuMedics has developed anti-inflammatory compounds that also have anti VEGF properties. They are designed for topical delivery to the eye to treat Diabetic Macular Edema (DME). DME is the leading cause of blindness for 2.5 million diabetic patients in U.S.; 75,000 new cases each year in U.S. Patients suffering from this disease are limited to expensive Biologic drugs or steroids and require frequent direct injections into the eye.

Team

  • Default avatar
    William Schwieterman M.D.,CMO
    VP and Chief Medical Officer

    Expert in the clinical development of a wide range of investigational therapeutic agent and spent 10 years as a Supervisor at the FDA and as a clinical reviewer on numerous biological and pharmaceutical-based agents including Enbrel, Remicade, Pegasys, Xigris and Zenapax, and has written numerous FDA guidance documents. Dr Schwieterman is a board-certified internist and a rheumatologist.

  • Default avatar
    Carl Osborne, D.V.M.
    V.P. of Development

    Over 19 years of experience in all phases of drug development and commercialization.Dr Osborne is veterinarian, toxicologist, and former FDA compliance officer and has been involved in the development of over 350 products world-wide.

  • Default avatar
    Iain Duncan
    CEO

    Sixteen years in small and startup pharma in executive positions and 20 years in various fortune 50 Corporations.VP Manufacturing and Supply Chain Operations, Horizon Therapeutics with responsibility for Product Development, Manufacturing, Quality Control, Distribution and Logistics functions. Mr Duncan formulated and developed Horizons’ lead product, DUEXIS© (patent pending). Co- founder of NeuMedics, co founder of Corus Pharma Inc.

Advisors

  • Default avatar
    Johnston Law Firm, PLLC
    Lawyer
    Unconfirmed
    Default avatar
    White Thompson & Co., PS
    Accountant
    Unconfirmed
    Default avatar
    Dr Sophie Bakri
    Scientific Advisor
    Unconfirmed
  • Default avatar
    Maria B. Grant, M.D., FARVO Marilyn K. Glick Senior Professor of Ophthalmology
    Unconfirmed